6,846 press releases indexed under healthcare.
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
Yoga India Foundation is a leading yoga teacher training school in Rishikesh, India, offering Yoga Alliance-certified programs. With over 5,000 students trained from 90+ countries, the school provides authentic, traditional yoga education in a peaceful ashram setting. Programs include 100, 200, 300, and 500-hour courses,
(PR-inside.com) Ayrmid Appoints Ideogen as Exclusive Partner for Omisirge® across Multiple Regions in Europe, MENA and CIS Ideogen granted exclusive rights to launch a managed access program for Omisirge across 55 markets, covering both FDA-approved Omisirge indications DUBLIN, IE / ACCESS Newswire / September 1, 2026 / Ayrmid Ltd. ("Ayrmid" or the "Company"), parent company of Gamida Cell Inc., today announced the appointment of Ideogen Group GmbH ("Ideogen") as its exclusive distributor for Omisirge® (omidubicel-onlv). Under the agreement, Ideogen is granted exclusive rights to launch a managed access program for Omisirge across 55 markets in Europe (excluding Greece and Cyprus), the Middle East ..
Austin, Texas--(Newsfile Corp. - September 1, 2026) - As the weight of stress, emotional overwhelm, and pervasive uncertainty continue to impact everyday life, Dr. Celeste Birkhofer's Beyond Quick Fixes: Essential Ingredients for Better Mental Health and a Fulfilling Life (Greenleaf Book Group Press, Sept 1, 2026, $23.95) provides a timely, research-informed guide to help move beyond reactive, superficial remedies to cultivate meaningful transformation and resilience. This book serves as a...
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced a strategic partnership with Koning Corporation ("Koning"), manufacturer of the FDA-approved Koning Vera Breast CT.Highlights:FDA-Approved Breast CT: The Koning Vera Breast CT is the only breast CT system with FDA premarket approval for diagnostic imaging of the breast....
ChatGPT can now connect to trusted healthcare data, helping clinicians securely access patient context, medical research, and more.
Ten-year Partnership Combines Loamara’s Product Development Expertise With myRocky’s Clinical Platform and Experience Supporting More Than 400,000 Patients TORONTO, ONTARIO - September 1, 2026 ( NEWMEDIAWIRE ) - Loamara Co. , the wellness company behind Green Monke, today announced a ten-year strategic partnership with Rocky Health Inc. (“myRocky”), a leading Health Canada approved digital health platform, to launch Loamara Wellness, a new product line focused on longevity, nutrition and proactive health. The first products will focus on supporting people using GLP 1 medications, alongside protein rich powders designed to support broader nutrition and wellness needs. Additional capsule, powder and gummy formats are expected to follow. The companies are targeting a commercial launch through
Bridging the gap between ICHRA and Medicare: Two industry leaders combine tax-free health allowances and zero-cost advocacy to combat rising healthcare costs for the aging workforce. The Problem: Standard ICHRA platforms lack Medicare integration, leaving aging workers to navigate complex...
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9...
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.
Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with six patients enrolled to date. Three participants have been enrolled at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C (“phase IIa”) following the successful completion of the tria